Find a clinical trial

What is the aim of the study? 

The main aim of the PrevenTRON study is to find out if a new medicine called trontinemab can help stop or slow down the development of Alzheimer’s disease before it causes memory and thinking problems.

Here is what the study is testing: 

• Helping before symptoms start: The study focuses on adults who currently have no problems with their memory or thinking, but who have changes in their brain or blood that may be linked to Alzheimer's disease. For example, they may have a build-up of a protein called amyloid, which can increase the chance of developing Alzheimer's disease in the future. 
• Testing a new way to reach the brain: Trontinemab is designed to find amyloid in the brain and help remove it. Getting medicines into the brain can be difficult because the brain has a protective barrier that blocks many medicines. Trontinemab uses a special method called 'Brainshuttle' to help the medicine cross this barrier and reach the brain.
• Comparing treatments: Some people in the study will get trontinemab, while others will get a placebo (a treatment that looks the same but has no medicine in it). Researchers will compare the groups over several years to see if the medicine helps keep people's brains healthy for longer.

In short, the study aims to prove whether treating the root causes of Alzheimer's disease before memory loss appears an effective way to stop or slow the disease. 

What will you be asked to do during the study? 

• Eligibility Screening (Up to 10 weeks): Complete basic health checks, blood tests, brain scans and memory questionnaires to see if you can join the study.
• Treatment Schedule (4 to 6 years): Receive monthly intravenous (IV) infusions of either the study drug or a placebo for the first 6 months, followed by maintenance infusions once every 6 months thereafter. 
• Safety & Memory Tracking: Complete interactive memory tests on a tablet and undergo safety brain MRI scans roughly every 6 months. 
• Observations & Pre-Medications: Take standard pre-medications (paracetamol and a steroid) to prevent side effects before each infusion, then stay at the clinic for 1 to 2 hours of observation. 
• Mandatory Study Partner: Bring a close friend or family member to appointments who can answer brief questionnaires about your day-to-day routine. 

What is the aim of the study?

Memory and thinking problems (sometimes called cognitive impairment) can be caused by damage to the small blood vessels of the brain. This is called small vessel disease. It is the commonest cause of vascular cognitive impairment and vascular dementia.

At the moment there is no specific treatment for the thinking and memory problems caused by small vessel disease.

Researchers have been studying two medicines, cilostazol and isosorbide mononitrate, which are already used to treat other health conditions. Previous studies suggest that these medicines may help protect the brain's small blood vessels from further damage. They have also been shown to be safe and well tolerated by people who have had a stroke caused by small vessel disease.

The aim of the LACI-Cog-1 trial is to research if these drugs could also help people with memory or thinking problems due to small vessel disease.

What will participants be asked to do during the study?

People in the study will be put into their treatment groups by chance, like flipping a coin. There are 4 treatment options that a person could be given:

• Isosorbide mononitrate
• Cilostazol
• Both medications together
• Neither medication (usual care only)

The study treatment will be given as a tablet.

During the study, participants will:

• Have brain scans called magnetic resonance imaging (MRI) scans. These scans take detailed pictures of the brain to help doctors check brain health and safety
• Complete tests that look at memory, thinking, and emotional wellbeing

If participants would like more details about the tests, procedures, or number of visits, the study team can provide full information.

What is the aim of the study?

This study is testing a new medicine called MK2214 in people with early Alzheimer's disease.

Researchers want to find out if MK2214 can help slow the build-up of a protein called tau in the brain. Tau can form harmful clumps that may damage brain cells and contribute to Alzheimer's disease.

The study will compare MK2214 with a placebo. A placebo looks the same as the study medicine but contains no active drug. Comparing the two helps researchers understand whether MK2214 works.

The main aims of the study are to see whether MK2214 can reduce tau levels in the brain and to check that it is safe.

What will participants be asked to do during the study?

Taking part in the study you will receive either MK-2214 or the placebo through a small tube placed into a vein in their arm. This is called an IV infusion or a drip. They will have this treatment once every 4 weeks while they are in the study.

You will be assigned to a treatment group by chance, like flipping a coin. Some people will receive MK2214 and some will receive the placebo.

Neither participants nor the study doctors will know who is receiving MK2214 or the placebo during the study. This helps ensure the results are fair and unbiased.

MK2214 is an experimental medicine. It has not yet been approved by health authorities for the treatment of Alzheimer's disease.

Find more information about why studies use blinding, randomisation and placebo controls.

During the study, you will:

Have blood and urine tests. These help doctors make sure the medicine is safe and check for any changes in health

• Have brain scans. These scans take detailed pictures of the brain so doctors can see how healthy it is and check that the treatment is safe
• Take part in activities and tests that look at memory, thinking skills, and wellbeing

If you would like more details about the tests, procedures, or number of visits, the study team can provide more information.

Tau is a protein which helps support brain cells. However, in Alzheimer’s disease, too much tau can clump together and cause damage which may lead to memory and thinking problems. This study is testing a new medicine called DNL628. This medicine may lower the amount of tau which may help slow the disease.

What is the aim of the study?
 

In this research study involving people with Alzheimer’s disease, we will be testing:

• if the study drug is safe and well tolerated
• how much of the study drug people can safely receive
• how the body processes the study drug
• how much the study drug reaches the brain, and whether it changes the tau protein levels
• how memory, thinking and brain scans may change with treatment.

What will participants be asked to do during the study?

During the study, participants will:

• have a physical and neurological examination, including recording your height and weight
• have some laboratory tests, such as blood or urine. These tests help doctors check for any new side effects, such as symptoms or health changes that might happen after receiving the study medicine
• complete tests that look at memory, thinking, and emotional wellbeing
• have brain scans called PET scans and magnetic resonance imaging (MRI) scans. These scans take detailed pictures of the brain to help doctors check brain health and safety.
   

What is the aim of the study?

This study is testing a new investigational medicine called LY3954068 for people with Alzheimer’s disease.

LY3954068 is an investigational treatment that is intended to help the body make less of a protein called tau. Tau helps support brain cells, but in Alzheimer’s disease, too much tau can clump together and cause damage which may lead to memory and thinking problems. This medicine is designed to lower the amount of tau so that these harmful clumps form more slowly, which may help slow the disease.

The study aims to understand:

• If LY3954068 is safe for people with Alzheimer’s disease and to see how well people can tolerate it.
• How LY3954068 works inside the body, including what it does and how the body handles it after it is given.

The LY3954068 or placebo is given as an injection into the space around the spine so it can reach the brain more directly.

This study is a double-blind placebo-controlled trial and people in the study will be put into their treatment groups at random. This means:

• Some people will get LY3954068
• Some people will get a placebo (a dummy treatment that has no medicine in it).
• Neither the participant, nor their study doctor will know who is getting which treatment during the first part of the study. This helps make the results fair.

Find more information about why studies use blinding, randomisation and placebo controls.

The study is made up of two parts, A and B.

• Each participant in Part A will receive 1 dose of LY3954068 or placebo (no active drug) given into the spinal fluid.
• Each participant in Part B will receive multiple doses of either LY3954068 or placebo administered into the spinal fluid.
• Participants will also potentially have an opportunity to join a separate study where participants would receive LY3954068.

LY3954068 is an experimental medicine. This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved LY3954068 for the treatment of Alzheimer’s disease.

The study also uses a drug called Flortaucipir F18 to monitor changes in the brain linked to Alzheimer’s disease. Flortaucipir F18 is a special type of medicine that gives off a very small amount of radiation. Medicines like this are called radiopharmaceuticals. Doctors use them before scans to help take clear pictures inside the body. Everyone in the study will have Flortaucipir F18 before their positron emission tomography (PET) scans. 

What will participants be asked to do during the study?

During the study, participants will:

• Have some laboratory tests, such as blood, urine or spinal fluid tests. These tests help doctors check for any new side effects, such as symptoms or health changes that might happen after receiving the study medicines or placebo.
• Have brain scans called PET scans and magnetic resonance imaging (MRI) scans. These scans take detailed pictures of the brain to help doctors check brain health and safety.
• Complete tests that look at memory, thinking, and emotional wellbeing.

The study will last up to approximately 45 weeks for Part A, and, 100 weeks for Part B, including the screening period.

If participants would like more details about the tests, procedures, or number of visits, the study team can provide full information.